SLC5A2 and kidney disorder: SGLT2 inhibitors including canagliflozin (CANA) and dapagliflozin (DAPA) have been shown to slow the progression of kidney disease, as well as reduce the risk of kidney failure, as reported in the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) [13] and DAPA-CKD [14] trials respectively.